Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HAIKU

Financiado

Cerrado

A breakthrough alternative to antibiotics for preventing and curing infectious d...

A breakthrough alternative to antibiotics for preventing and curing infectious diseases at Intensive Care Units Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibio... ver más

31/05/2019

REMAB THERAPEUTICS

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

REMAB THERAPEUTICS El desarrollo y comercializacion de productos que permitan la eliminacion de anticuerpos y en especial, generacion de tratamientos para las...

TRL 3-4 | 216K€

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-05-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

REMAB THERAPEUTICS

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121544-I00 DISEÑO DE UNA NUEVA CLASE DE ANTIMICROBIANOS CONTRA INFECCIO... 133K€ Cerrado

COMBACTE-MAGNET Combatting Bacterial Resistance in Europe Molecules agains... 169M€ Cerrado

ENABLE European Gram Negative Antibacterial Engine 101M€ Cerrado

AB-DiRecT Antibiotic Distribution and Recovery in Tissue 4M€ Cerrado

PID2019-105512RB-I00 COMBATIENDO LAS BACTERIAS RESISTENTES A LOS ANTIBIOTICOS Y C... 169K€ Cerrado

ENABLE European Gram Negative Antibacterial Engine 101M€ Cerrado

Duración del proyecto: 3 meses Fecha Inicio: 2019-02-05
Fecha Fin: 2019-05-31

Líder del proyecto

REMAB THERAPEUTICS El desarrollo y comercializacion de productos que permitan la eliminacion de anticuerpos y en especial, generacion de tratamientos para las...

TRL 3-4 | 216K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hospital-acquired infections are a major cause of morbidity, mortality and costs in Intensive care units (ICUs) worldwide. The most critical infectious group consist of Gram-negative bacteria that are resistant to multiple antibiotics. We have developed RA-01, a novel drug product and a first line therapy for preventing and curing infectious diseases at ICUs based on the removal of inhibitory antibodies, which are used by bacteria to facilitate their infectivity. This new drug allows an immediate protection to patients admitted to ICU without generating antimicrobial resistance (AMR). RA-01 will reduce public/private healthcare systems costs and improve a social benefit by freeing up hospital beds: €9,150 reduction in treatment costs, 7 days less at ICU and €15 k reduction in ICU costs. Currently, our competitors are focused on new antibiotics and antibodies, so there are no other companies working in the removing of specific antibodies as a preventive and curative method for infectious diseases. The total potential market is estimated to be >13 million patients/year. From this market, will be target ICU patients at risk for prolonged stays: >4 million patients. RemAb Therapeutics is a biotech company that develops a novel class of medicines by removing natural specific antibodies. Our mission is to advance our portfolio of therapies to clinical trials and improve the lives of patients and families affected by infectious diseases. Our drug molecule will be developed and de-risked through clinical trials-Ph2 and then licensed to pharma companies, to finalise their development and bring them to the market By 2026 we expect to reach: a) 14% royalties’ rate on net sales with a RA-01 price to healthcare systems of €800-1000 (complete treatment); b) Total addressable market growing up to about €275 m; c) Net present value of €21.4 m (10% discount rate) and an IRR of 56%; d) Cumulative EBITDA over €23 m; e) 6% market share (240,000 patients); f) 15 newly created jobs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores